Core Insights - The year 2025 marks a milestone for China's ETF market, with the overall scale surging from 3.73 trillion yuan at the end of 2024 to 6.02 trillion yuan, reflecting a growth rate of 61.4% [1] - The fund flow shows significant characteristics, with industry-themed ETFs and broad-based ETFs leading the way, highlighting a dual strategy of technology innovation and high dividend yields [1] Group 1: ETF Market Growth - By the end of 2025, the ETF market in China is projected to reach 6.02 trillion yuan, a substantial increase from 3.73 trillion yuan in 2024 [1] - The growth is driven by favorable policies and market recognition, indicating a robust future for ETF investments [1] Group 2: Performance of Jiashi Fund - Jiashi Fund's ETF products have diversified, with a total scale exceeding 369.6 billion yuan and 61 ETF products, of which 24 rank first in their respective categories [1] - The flagship product, the CSI 300 ETF, has a scale of 197.12 billion yuan, ranking first among similar products on the Shenzhen Stock Exchange [2] - The Jiashi Fund's innovative bond ETFs, particularly the Sci-Tech Bond ETF, have surpassed 43.67 billion yuan, becoming the largest in its category [2] Group 3: Thematic and Sector ETFs - Jiashi Fund's software ETF has reached a scale of nearly 14.5 billion yuan, becoming the largest in its index category, reflecting the growth potential of the software industry in the digital economy [3] - The rare metals ETF and rare earth ETF have also seen significant growth, with scales of 6.36 billion yuan and 9.26 billion yuan respectively, providing crucial links for investments in new energy and high-end manufacturing [3] - The Sci-Tech Chip ETF has a scale of 46.91 billion yuan, leading in its category and showcasing Jiashi Fund's strategic positioning in the semiconductor industry [3] Group 4: Cross-Border ETF Development - By the end of 2025, Jiashi Fund's cross-border ETF products have expanded, with the NASDAQ ETF reaching 10.07 billion yuan and the Germany ETF exceeding 2 billion yuan [4] - These products facilitate investments in U.S. tech stocks and European core economies, enhancing the fund's global investment matrix [4] Group 5: Future Outlook - Jiashi Fund aims to refine its index investment capabilities and continuously optimize its ETF product line to align with national strategies and technological innovations [5] - The focus is on providing efficient, precise, and high-quality investment tools to help investors seize market opportunities and achieve long-term wealth growth [5]

Group 1 - The core viewpoint of the news highlights the positive performance of the innovative drug sector in the stock market, with significant gains in individual stocks and ETFs [1][3] - The new national medical insurance drug catalog will be implemented on January 1, 2026, adding 114 new drugs, including 50 Class 1 new drugs, marking a record high in both quantity and proportion [2] - The commercial insurance catalog will include 19 high-value innovative drugs, addressing accessibility issues for high-value innovative treatments [2] Group 2 - The collaboration between domestic innovative drug companies and multinational corporations continues, with 49 outbound transactions totaling over $39 billion since October last year [3] - The market is entering a peak season for business development (BD) and data disclosures, coinciding with the JPM conference and the upcoming annual report cycle [3] - The Hong Kong Stock Connect Innovative Drug ETF (520970) tracks the CSI Hong Kong Stock Connect Innovative Drug Index, with the top ten weighted stocks accounting for over 71.95% of the total weight [3]

Group 1 - The core viewpoint of the news is that the Hong Kong stock market's innovative drug index is experiencing growth, indicating a positive trend in the pharmaceutical sector, particularly in innovative drugs [1] - As of 09:40, the Hong Kong Stock Connect innovative drug index rose by 1.59%, with individual stocks like Kangfang Biotech increasing over 3%, and others such as Kelun-Bio, CSPC Pharmaceutical, and Hansoh Pharmaceutical rising over 2% [1] - The report from Donghai Securities suggests that by 2026, China's pharmaceutical and biotechnology industry will enter a new era of innovative drugs, which will gradually dominate the sector, supported by the complementary relationship between medical insurance and commercial insurance [1] Group 2 - The Hong Kong Stock Connect innovative drug ETF, managed by Harvest (520970), tracks the CSI Hong Kong Stock Connect Innovative Drug Index, with the top ten weighted stocks accounting for over 71.71% of the total weight [2] - The management and custody fees for the Harvest innovative drug ETF are 0.60% per year, making it suitable for both ordinary investors as a long-term investment tool and for professional investors seeking flexible trading options [2]

Group 1 - The core viewpoint of the news is that the A-share and Hong Kong markets are experiencing a collective rise, with the Shanghai Composite Index surpassing 4000 points, indicating positive market sentiment [1] - The Hong Kong Stock Connect innovative drug index increased by 3.85%, with notable individual stock performances such as Zhaoyan New Drug rising over 11% and Tigermed and Kelun-Bio rising over 6% [1] - According to a report by Changjiang Securities, Zhaoyan New Drug is expected to see a 60% year-on-year growth in offshore outsourcing orders in 2024, driven by domestic safety evaluation demand recovery and resource scarcity [1] Group 2 - The China National Medical Products Administration reported that 76 innovative drugs have been approved for market in China by 2025, setting a historical record [1] - The total amount of authorized transactions for innovative drugs in China has exceeded $130 billion, with over 150 transactions, also a historical high [1] - Currently, China's pipeline of new drugs accounts for approximately 30% of the global total, ranking second worldwide [1] Group 3 - The Hong Kong Stock Connect innovative drug ETF managed by Harvest (520970) has a management and custody fee of 0.60% per year, making it suitable for both retail investors as a long-term investment tool and for professional investors seeking flexible trading options [2]